Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
Yes, perimenopause can intensify ADHD symptoms, because declining and fluctuating estrogen reduces dopamine activity in the brain, which is central to attention, memory, and emotional regulation. Many women report worsening focus, forgetfulness, disorganization, irritability, and brain fog in their late 30s to early 50s, and some are diagnosed with ADHD for the first time during this stage. Symptoms can overlap with thyroid conditions, anemia, depression, anxiety, and sleep disruption, so worsening focus is not always explained by hormones alone. Treatment adjustments, including medication timing or dosage changes and discussion of hormone therapy, may help, but there are several important factors to consider, so see below for the complete answer.
If your focus, memory, or mood has shifted and you are unsure whether hormones, ADHD, or something else is driving it, a free, instant, online symptom check can help you organize your symptoms, see which conditions may match, and walk into your next appointment ready to ask the right questions.
Last reviewed for medical accuracy: 09/24/2026
Perimenopause—the transitional phase leading up to menopause—brings fluctuating hormone levels, especially estrogen and progesterone. For people with attention-deficit/hyperactivity disorder (ADHD), these hormonal shifts can magnify existing symptoms or even trigger new challenges. Understanding why this happens and how to address it can help you stay on top of your mental sharpness and emotional well-being.
Estrogen influences the brain’s neurotransmitter systems, notably dopamine and norepinephrine, which are key to focus, motivation, and mood regulation. In perimenopause:
These hormone swings can disrupt the neural circuits that people with ADHD already rely on stronger regulation of. In practice, you might notice:
While every experience is unique, here are some ADHD symptoms that often feel more intense during perimenopause:
A multi-pronged approach—combining medical treatments, lifestyle adjustments, and behavioral strategies—often works best. Here’s what to consider:
Before making changes, discuss your symptoms with your doctor or a menopause specialist. They can:
If you already take ADHD medication, your tolerance or symptom control may shift during perimenopause. Your doctor might review:
These “common medications for ADHD” can be fine-tuned in dosage or timing to offset perimenopause-related dips in concentration and energy.
For some, low-dose estrogen or combined estrogen-progesterone therapy helps stabilize mood and cognitive function. Benefits may include:
HT isn’t right for everyone. Weigh benefits against risks (e.g., blood clots, breast tenderness) under medical supervision.
A therapist skilled in CBT for adult ADHD can teach:
Not sure if your current experience is perimenopause-related or purely ADHD? Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you track patterns and decide what to discuss with your healthcare provider.
While mood swings and focus issues are often manageable, certain signs require prompt medical attention:
If you experience any of these, call emergency services or go to your nearest emergency department.
Perimenopause can amplify ADHD symptoms through hormonal fluctuations that affect focus, mood, and sleep. A tailored approach—combining medical treatment (including adjustments to common ADHD medications), hormone therapy when appropriate, and lifestyle strategies—can help you regain control. Start by tracking your symptoms, consider the Ubie Symptom Checker, and most importantly, speak to a doctor or menopause specialist about your concerns. With the right support, you can navigate this transition while keeping your ADHD well-managed.
(References)
* de Jong M, Wynchank DSMR, Michielsen M, Beekman ATF, Kooij JJS. A Female-Specific Treatment Group for ADHD-Description of the Programme and Qualitative Analysis of First Experiences. J Clin Med. 2024 Apr 4;13(7). doi: 10.3390/jcm13072106. Epub 2024 Apr 4. PMID: 38610871; PMCID: PMC11012758.
* Craddock E. Being a Woman Is 100% Significant to My Experiences of Attention Deficit Hyperactivity Disorder and Autism: Exploring the Gendered Implications of an Adulthood Combined Autism and Attention Deficit Hyperactivity Disorder Diagnosis. Qual Health Res. 2024 Dec;34(14):1442-1455. doi: 10.1177/10497323241253412. Epub 2024 Jul 18. PMID: 39025117; PMCID: PMC11580322.
* Kooij JJS, de Jong M, Agnew-Blais J, Amoretti S, Bang Madsen K, Barclay I, Bölte S, Borg Skoglund C, Broughton T, Carucci S, van Dijken DKE, Ernst J, French B, Frick MA, Galera C, Groenman AP, Kopp Kallner H, Kerner Auch Koerner J, Kittel-Schneider S, Manor I, Martin J, Matera E, Parlatini V, Philipsen A, Ramos-Quiroga JA, Rapoport IL, Remnélius KL, Sénéquier A, Thorell L, Wittekoek JME, Wynchank D. Research advances and future directions in female ADHD: the lifelong interplay of hormonal fluctuations with mood, cognition, and disease. Front Glob Womens Health. 2025;6:1613628. doi: 10.3389/fgwh.2025.1613628. Epub 2025 Jul 7. PMID: 40692967; PMCID: PMC12277363.
* Jakobsdóttir Smári U, Valdimarsdottir UA, Wynchank D, de Jong M, Aspelund T, Hauksdottir A, Thordardottir EB, Tomasson G, Jakobsdottir J, Lu D, Nevriana A, Larsson H, Kooij S, Zoega H. Perimenopausal symptoms in women with and without ADHD: A population-based cohort study. Eur Psychiatry. 2025 Sep 4;68(1):e133. doi: 10.1192/j.eurpsy.2025.10101. Epub 2025 Sep 4. PMID: 40903825; PMCID: PMC12538516.
* Wynchank D, de Jong M, Kooij SJJS. Practical tools for female-specific ADHD: The impact of hormonal fluctuations in clinical practice and from the literature. Eur Psychiatry. 2025 Oct 21;69(1):e1. doi: 10.1192/j.eurpsy.2025.10120. Epub 2025 Oct 21. PMID: 41115846; PMCID: PMC12816923.
* Krebs K, Donnellan-Fernandez R. Integrative literature review - the impact of ADHD across women's lifespan. BMC Womens Health. 2025 Dec 8;25(1):593. doi: 10.1186/s12905-025-04123-1. Epub 2025 Dec 8. PMID: 41361438; PMCID: PMC12683802.
* Werwath KE, Lawn RB, Salem MT, Li T, Mitchell BL, Shen H, Gordon SD, Kung B, Stafford C, Vemuri M, Ratanatharathorn A, Meijsen J, Shadyab AH, Kooperberg C, Koenen KC, Crandall CJ, Martin NG, Duncan LE. Trans-ancestry GWAS of hot flashes reveals potent treatment target and overlap with psychiatric disorders. Commun Med (Lond). 2026 Jan 6;6(1):51. doi: 10.1038/s43856-025-01305-8. Epub 2026 Jan 6. PMID: 41495267; PMCID: PMC12830824.
* Wynchank D, Kooij S. Pharmacological Management of ADHD in Women Across Perimenopause, Menopause and Post-Menopause. Drugs Aging. 2026 May;43(5):385-395. doi: 10.1007/s40266-026-01291-z. Epub 2026 Apr 22. PMID: 42018215; PMCID: PMC13149623.
* Kini-Seery C, Trevaskis S, Kilbride K, Wrigley M, Bramham J. "Hormones rule me": A qualitative exploration of the impact of perimenopause on women with ADHD. Womens Health (Lond). 2026 Jan-Dec;22:17455057261450178. doi: 10.1177/17455057261450178. Epub 2026 Jul 17. PMID: 42466994; PMCID: PMC13379672.
* Moseley RL, Gamble-Turner JM, Kim E, Spencer C. Autism, ADHD and the menopause. Post Reprod Health. 2026 Sep;32(3):145-155. doi: 10.1080/20533691.2026.2631222. Epub 2026 Mar 9. PMID: 42484392.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.